MCID: ESP024
MIFTS: 63

Esophagitis

Categories: Gastrointestinal diseases, Infectious diseases

Aliases & Classifications for Esophagitis

MalaCards integrated aliases for Esophagitis:

Name: Esophagitis 12 29 55 44 15 73
Acute Esophagitis 12 73

Classifications:



External Ids:

Disease Ontology 12 DOID:11963
ICD10 33 K20 K20.9
ICD9CM 35 530.1 530.10
MeSH 44 D004941
NCIt 50 C9224

Summaries for Esophagitis

MalaCards based summary : Esophagitis, also known as acute esophagitis, is related to esophageal cancer and peptic esophagitis, and has symptoms including pain in esophagus (finding) An important gene associated with Esophagitis is CCL26 (C-C Motif Chemokine Ligand 26), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Dexlansoprazole and Lansoprazole have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and endothelial, and related phenotypes are growth/size/body region and homeostasis/metabolism

Wikipedia : 76 Esophagitis (or oesophagitis) is an inflammation of the esophagus. The prefix esophag/o refers to the... more...

Related Diseases for Esophagitis

Diseases in the Esophagitis family:

Bacterial Esophagitis Viral Esophagitis

Diseases related to Esophagitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 865)
# Related Disease Score Top Affiliating Genes
1 esophageal cancer 33.8 CXCL8 EGFR IL6 PTGS2 TP53
2 peptic esophagitis 33.6 CXCL8 CYP2C19 HRH2 IL1B
3 kaposi sarcoma 30.9 CCR3 CXCL8 IL6 TP53
4 laryngitis 30.8 HRH2 IL1B IL6
5 pharyngitis 30.8 CXCL8 IL1B PTGS2
6 atrophic gastritis 30.7 CXCL8 IL1B TP53
7 prostatitis 30.5 CXCL8 IL1B IL6
8 chagas disease 30.5 CXCL8 IL1B IL6
9 esophagitis, eosinophilic, 1 30.4 CCL11 CCL26 DSG1 IL13 IL5 POSTN
10 gastritis 30.4 CXCL8 HRH2 IL1B PTGS2
11 gastric adenocarcinoma 30.3 CXCL8 EGFR IL1B PTGS2 TP53
12 vaginitis 30.2 CXCL8 IL1B IL6
13 helicobacter pylori infection 30.2 CXCL8 CYP2C19 EGFR IL1B TP53
14 esophageal disease 30.2 CCL26 CYP2C19 HRH2 IL13 IL5 PTGS2
15 acute respiratory distress syndrome 30.1 CXCL8 IL1B IL6
16 duodenal ulcer 30.1 CXCL8 CYP2C19 HRH2 IL1B
17 interstitial lung disease 30.1 CXCL8 EGFR IL1B IL6
18 colitis 30.1 CXCL8 IL1B IL6 PTGS2
19 gastroesophageal reflux 30.1 CCL26 CXCL8 CYP2C19 HRH2 IL1B IL5
20 gingivitis 30.1 CXCL8 IL1B IL6
21 osteomyelitis 30.1 CXCL8 IL1B IL6
22 colorectal adenocarcinoma 30.0 EGFR PTGS2 TP53
23 oral cancer 30.0 EGFR PTGS2 TP53
24 placenta disease 29.9 CXCL8 IL1B IL6
25 pneumoconiosis 29.9 CXCL8 IL1B IL6
26 peritonitis 29.8 CXCL8 IL1B IL6
27 lung disease 29.8 CXCL8 IL13 IL1B IL5
28 squamous cell carcinoma, head and neck 29.7 CXCL8 EGFR PTGS2 TP53
29 meningitis 29.7 CXCL8 IL1B IL6
30 gastric ulcer 29.7 CXCL8 CYP2C19 HRH2 IL1B PTGS2
31 periodontitis 29.7 CXCL8 IL1B IL6
32 peptic ulcer disease 29.7 CXCL8 CYP2C19 HRH2 IL1B PTGS2
33 interstitial cystitis 29.4 CXCL8 IL6 TRPV1
34 arthritis 29.4 CXCL8 IL1B IL6 PTGS2
35 central nervous system disease 29.1 IL1B IL6 TRPV1
36 ewing sarcoma 29.1 EGFR IL1B IL6 PTGS2 TP53
37 pulmonary fibrosis, idiopathic 29.0 CXCL8 IL13 IL1B POSTN
38 ulcerative colitis 29.0 CXCL8 IL1B IL6
39 gastroenteritis 28.9 CCL11 CXCL8 IL1B IL5 IL6
40 nervous system disease 28.8 IL1B IL6 TRPV1
41 autoimmune disease 28.8 DSG1 IL1B IL5 IL6
42 myocardial infarction 28.8 CYP2C19 IL1B IL6 POSTN PTGS2
43 dyspepsia 28.8 CXCL8 CYP2C19 HRH2 PTGS2 TRPV1
44 cystitis 28.7 CXCL8 IL6 PTGS2 TP53 TRPV1
45 bronchitis 28.7 CCL11 CXCL8 IL5
46 hypereosinophilic syndrome 28.4 CCL11 IL13 IL5
47 pneumonia 28.3 CCL11 CXCL8 IL13 IL1B IL5 IL6
48 bullous pemphigoid 28.2 CCL11 DSG1 IL5
49 keratoconjunctivitis 28.2 CCL11 CXCL8 IL13 IL5
50 eosinophilic gastritis 28.2 CCL11 CCL26 IL13 IL5

Comorbidity relations with Esophagitis via Phenotypic Disease Network (PDN): (show top 50) (show all 112)


Active Peptic Ulcer Disease Acute Cystitis
Acute Maxillary Sinusitis Acute Pancreatitis
Alcoholic Gastritis Allergic Rhinitis
Angina Pectoris Anxiety
Aortic Valve Disease 1 Atrophic Gastritis
Basilar Artery Insufficiency Benign Essential Hypertension
Bronchiectasis Bronchitis
Bronchopneumonia Cerebrovascular Disease
Cholecystitis Cholestasis
Chronic Intestinal Vascular Insufficiency Chronic Kidney Failure
Chronic Maxillary Sinusitis Chronic Myocardial Ischemia
Chronic Pulmonary Heart Disease Chronic Rhinitis
Chylomicron Retention Disease Conn's Syndrome
Conversion Disorder Cystitis
Deficiency Anemia Dependent Personality Disorder
Dermatomycosis Diabetic Polyneuropathy
Duodenitis Dyskinesia of Esophagus
Dysthymic Disorder Esophageal Cancer
Esophageal Candidiasis Esophageal Disease
Esophageal Varix First-Degree Atrioventricular Block
Gallbladder Disease Gastrin Secretion Abnormality
Gastritis, Familial Giant Hypertrophic Gastroesophageal Reflux
Generalized Anxiety Disorder Generalized Atherosclerosis
Heart Disease Hepatitis
Hyperlipoproteinemia, Type Iv Hyperlipoproteinemia, Type V

Graphical network of the top 20 diseases related to Esophagitis:



Diseases related to Esophagitis

Symptoms & Phenotypes for Esophagitis

UMLS symptoms related to Esophagitis:


pain in esophagus (finding)

MGI Mouse Phenotypes related to Esophagitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.17 TP53 TRPV1 POSTN TSLP PTGS2 EGFR
2 homeostasis/metabolism MP:0005376 10.15 TP53 TRPV1 POSTN TSLP PTGS2 EGFR
3 hematopoietic system MP:0005397 10.14 TP53 POSTN TSLP PTGS2 IL6 IL13
4 immune system MP:0005387 10.1 TP53 TRPV1 POSTN TSLP PTGS2 IL6
5 digestive/alimentary MP:0005381 10.06 TP53 TSLP PTGS2 HRH2 IL6 IL13
6 adipose tissue MP:0005375 10.02 TP53 TRPV1 POSTN PTGS2 IL6 DSG1
7 integument MP:0010771 9.91 TP53 TRPV1 TSLP PTGS2 IL6 IL13
8 neoplasm MP:0002006 9.76 TP53 TRPV1 PTGS2 POSTN IL1B IL5
9 respiratory system MP:0005388 9.61 TP53 TSLP PTGS2 IL13 CCL11 CCR3
10 skeleton MP:0005390 9.23 PTGS2 TP53 POSTN EGFR IL6 IL13

Drugs & Therapeutics for Esophagitis

Drugs for Esophagitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 296)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexlansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 138530-94-6, 103577-45-3 9578005
2
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 103577-45-3 3883
3
Domperidone Approved, Investigational, Vet_approved Phase 4,Not Applicable 57808-66-9 3151
4
Dopamine Approved Phase 4,Not Applicable 51-61-6, 62-31-7 681
5
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 73590-58-6 4594
6
Rabeprazole Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 117976-89-3 5029
7
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 161796-78-7, 119141-88-7 4594 9579578
8
Fluticasone Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 90566-53-3 62924
9
Menthol Approved Phase 4,Phase 3,Not Applicable 2216-51-5 16666
10
Pantoprazole Approved Phase 4,Phase 3,Phase 2 102625-70-7 4679
11
Budesonide Approved Phase 4,Phase 3,Phase 2,Not Applicable 51333-22-3 63006 5281004
12
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 150399-23-8, 137281-23-3 446556 60843
13
Ranitidine Approved Phase 4,Phase 3,Phase 1 66357-59-3, 66357-35-5 3001055
14
Trimebutine Approved Phase 4 39133-31-8
15
Deferasirox Approved, Investigational Phase 4 201530-41-8 5493381
16
Iron Approved Phase 4 7439-89-6 23925
17
Verapamil Approved Phase 4 52-53-9 2520
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 59-30-3 6037
19
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2 58-05-9 143 6006
20
Serine Approved, Nutraceutical Phase 4 56-45-1 5951
21 Rebamipide Investigational Phase 4 90098-04-7
22
Maleic acid Experimental Phase 4,Not Applicable 110-16-7 444266
23 Antacids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Proton Pump Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Antiemetics Phase 4,Not Applicable
28 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
29 Dopamine Agents Phase 4,Not Applicable
30 Dopamine Antagonists Phase 4,Not Applicable
31 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Anti-Allergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Bronchodilator Agents Phase 4,Phase 3,Phase 2,Not Applicable
38 Dermatologic Agents Phase 4,Phase 3,Phase 2,Not Applicable
39 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
40 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Protective Agents Phase 4,Phase 2,Phase 1
44 HIV Protease Inhibitors Phase 4,Phase 3,Phase 1
45
protease inhibitors Phase 4,Phase 3,Phase 1
46 Cromolyn Sodium Phase 4
47 Omeprazole, sodium bicarbonate drug combination Phase 4
48 Antioxidants Phase 4,Phase 2,Phase 1
49 Pepsin A Phase 4
50
Bilirubin Phase 4 635-65-4 5280352

Interventional clinical trials:

(show top 50) (show all 460)
# Name Status NCT ID Phase Drugs
1 Treatment Effect Between Dexlansoprazole and Double-dose Lansoprazole in Obesity Patients With Reflux Esophagitis Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
2 Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity Unknown status NCT02140073 Phase 4 omeprazole+domperidone SR;omeprazole
3 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
4 The Randomized Controlled Clinical Trial of Kushen Injection Unknown status NCT02346318 Phase 4 Compound Kushen Injection
5 An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis Completed NCT01008696 Phase 4 Rabeprazole;Lansoprazole
6 Intravenous (IV) Pantoprazole in Erosive Esophagitis Completed NCT00133770 Phase 4 pantoprazole
7 Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis Completed NCT02371941 Phase 4 oral cromolyn sodium;Placebo
8 Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study Completed NCT00693225 Phase 4 Omeprazole/sodium bicarbonate
9 Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy Completed NCT01874535 Phase 4 Esomeprazole 40 mg
10 A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Completed NCT00641602 Phase 4 Esomeprazole;Lansoprazole
11 Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis Completed NCT01846962 Phase 4 Budesonide;Fluticasone;Oral Viscous Budesonide (OVB)
12 Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation Completed NCT03116841 Phase 4 Vonoprazan
13 NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis Completed NCT00206180 Phase 4 esomeprazole magnesium (oral medication)
14 The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD Completed NCT01860482 Phase 4 Newrabell® Tablet 10mg
15 A Study to Evaluate REbamiPide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis Completed NCT02755753 Phase 4 Lansoprazole;Rebamipide;Rebamipide-placebo
16 Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed Completed NCT00644735 Phase 4 Esomeprazole;Lansoprazole
17 Esomeprazole for Treatment of GERD in Pediatric Patients Completed NCT00228527 Phase 4 Esomeprazole (Nexium)
18 An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00242736 Phase 4 Esomeprazole
19 Role of Pepsin Assay in Wheezy Infants Completed NCT02685436 Phase 4 Omeprazole and domperidone
20 To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole Completed NCT01397084 Phase 4 esomeprazole 20 mg
21 Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease Completed NCT02351960 Phase 4 Dexlansoprazole
22 The Prospective Study on the Effect of Ilaprazole in Non-erosive Reflux Disease Patients; Focused on Histologic Findings and Inflammatory Biomarker Completed NCT02666976 Phase 4 Ilaprazole
23 An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During the Fasting Month of Ramadan Completed NCT03079050 Phase 4 Dexlansoprazole 60 MG
24 Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients Completed NCT00574925 Phase 4 Esomeprazole
25 A Study of Rabeprazole and Pantoprazole on Stomach Acid and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD) and a History of Nighttime Heartburn Completed NCT00237367 Phase 4 rabeprazole and pantoprazole
26 Do Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment? Completed NCT00444145 Phase 4 Prevacid
27 Nissen and Gastroplasty in Gastroesophageal Reflux Disease (GERD) Completed NCT00872755 Phase 4
28 Chemotherapy for Patients With Non-Small Cell Lung Cancer Completed NCT00380718 Phase 4 pemetrexed
29 Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole Recruiting NCT02986685 Phase 4 Trimebutine Maleate;rabeprazole
30 Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis Recruiting NCT03372083 Phase 4 Deferasirox
31 Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation Recruiting NCT02067182 Phase 4 Dabigatran
32 Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety Active, not recruiting NCT02679508 Phase 4 Vonoprazan;Lansoprazole
33 Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis Active, not recruiting NCT02019758 Phase 4 Oral Viscous Budesonide;Fluticasone MDI;Placebo slurry;Placebo inhaler
34 Transoral Incisionless Fundoplication (TIF) Versus Sham for Treatment of Gastroesophageal Reflux Disease (GERD) Active, not recruiting NCT01110811 Phase 4
35 Efficacy of Zinc L-carnosine in Maintaining Remission of Gastroesophageal Reflux Disease Not yet recruiting NCT03467438 Phase 4 Zinc-l-carnosine
36 The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors Terminated NCT01404832 Phase 4 Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
37 Lansoprazole Preventing Gastroduodenal Stress Ulcerations Terminated NCT00220909 Phase 4 Lansoprazole
38 The Clinical Significance of Acid Rebound in Functional Dyspepsia Terminated NCT01373970 Phase 4 Placebo;Pantoprazole + Placebo
39 Dexilant Treatment in Gastrointestinal Reflux Disease (GERD Related Non Cardiac Chest Pain Withdrawn NCT01637571 Phase 4 Dexilant;Dexilant Placebo
40 Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone Unknown status NCT01702701 Phase 3 Montelukast;Fluticasone
41 Eosinophilic Esophagitis (EoE) Intervention Trial-Randomized 1 Food Elimination vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids Unknown status NCT02610816 Phase 2, Phase 3 Flovent (fluticasone propionate)
42 A Trial of Reconstruction After Distal Gastrectomy for Gastric Cancer Unknown status NCT01065688 Phase 3
43 Laparoscopic Repair of Giant Hiatal Hernias With Nitinol-framed Lightweight Polytetrafluoroethylene Mesh Unknown status NCT01780285 Phase 3
44 Laparoscopic Lightweight Mesh Repair of Large Hiatal Hernias Unknown status NCT01408108 Phase 3
45 Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis Completed NCT03006874 Phase 3 CJ-12420 100mg QD;Esomeprazole 40mg;CJ-12420 50mg QD
46 Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis Completed NCT02456935 Phase 3 CJ-12420 100 mg QD;Esomeprazole 40 mg QD
47 Reflux Esophagitis Phase III Study (Maintenance Treatment) Completed NCT00634114 Phase 3 Esomeprazole;Esomeprazole;Omeprazole
48 Reflux Esophagitis Phase III Study (Initial Treatment) Completed NCT00633932 Phase 3 Esomeprazole;Esomeprazole;Omeprazole
49 Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Erosive Esophagitis Completed NCT01452698 Phase 3 TAK-438;Placebo;Lansoprazole;Placebo
50 Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive Esophagitis Completed NCT01459367 Phase 3 TAK-438;TAK-438;Lansoprazole

Search NIH Clinical Center for Esophagitis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: esophagitis

Genetic Tests for Esophagitis

Genetic tests related to Esophagitis:

# Genetic test Affiliating Genes
1 Esophagitis 29

Anatomical Context for Esophagitis

MalaCards organs/tissues related to Esophagitis:

41
Lung, Lymph Node, Endothelial, Testes, Liver, Colon, Bone

Publications for Esophagitis

Articles related to Esophagitis:

(show top 50) (show all 10452)
# Title Authors Year
1
Outcomes of esophagectomy after chemotherapy with biweekly docetaxel plus cisplatin and fluorouracil for advanced esophageal cancer: a retrospective cohort analysis. ( 29966526 )
2018
2
The Prediction of Deterioration of Nutritional Status during Chemoradiation Therapy in Patients with Esophageal Cancer. ( 29324061 )
2018
3
Recent progress in perioperative management of patients undergoing esophagectomy for esophageal cancer. ( 29951987 )
2018
4
Esophageal achalasia and pregnancy: own observations in 43 patients and a review of the literature. ( 29931525 )
2018
5
Surgical management of esophageal sarcoma: a multicenter European experience. ( 29444281 )
2018
6
Pulmonary actinomycosis mimicking a lung metastasis from esophageal cancer; a case report. ( 29486747 )
2018
7
Eosinophilic Esophagitis Is a Late Manifestation of the Allergic March. ( 29954692 )
2018
8
Clinical Translation of Tethered Confocal Microscopy Capsule for Unsedated Diagnosis of Eosinophilic Esophagitis. ( 29422678 )
2018
9
Esophagography in Patients With Esophageal Achalasia Diagnosed With High-resolution Esophageal Manometry. ( 29969858 )
2018
10
Propofol improves the function of natural killer cells from the peripheral blood of patients with esophageal squamous cell carcinoma. ( 29977357 )
2018
11
Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer. ( 29948480 )
2018
12
Esophageal cancer male to female incidence ratios in Africa: A systematic review and meta-analysis of geographic, time and age trends. ( 29414631 )
2018
13
Anaphylatoxin C3a: A potential biomarker for esophageal cancer diagnosis. ( 29435296 )
2018
14
Structural airway abnormalities contribute to dysphagia in children with esophageal atresia and tracheoesophageal fistula. ( 29429770 )
2018
15
Gastroesophageal reflux symptoms are not sufficient to guide esophageal function testing in lung transplant candidates. ( 29444329 )
2018
16
Blind esophageal brushing offers a safe and accurate method to monitor inflammation in children and young adults with eosinophilic esophagitis. ( 29905784 )
2018
17
The Association Between Statin Use After Diagnosis and Mortality Risk in Patients With Esophageal Cancer: A Retrospective Cohort Study of United States Veterans. ( 29946180 )
2018
18
Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review. ( 29908360 )
2018
19
Course of Esophageal Candidiasis and Outcomes of Patients at a Single Center. ( 29702297 )
2018
20
The long non-coding RNA AK001796 contributes to tumor growth via regulating expression of p53 in esophageal squamous cell carcinoma. ( 29568233 )
2018
21
The Role of PET-Based Radiomic Features in Predicting Local Control of Esophageal Cancer Treated with Concurrent Chemoradiotherapy. ( 29967326 )
2018
22
Barrett Esophagus Length, Nodularity, and Low-grade Dysplasia are Predictive of Progression to Esophageal Adenocarcinoma. ( 29608452 )
2018
23
Impact of preoperative balloon dilatation on outcomes of laparoscopic surgery in young patients with esophageal achalasia. ( 29892807 )
2018
24
Multiple roles of single-minded 2 in esophageal squamous cell carcinoma and its clinical implications. ( 29427302 )
2018
25
Scintigraphic Evaluation of Esophageal Motility and Gastroesophageal Reflux in Patients Presenting with Upper Respiratory Tract Symptoms. ( 29430111 )
2018
26
Whole exome sequencing identifies a mutation in EYA1 and GLI3 in a patient with branchioa89otic syndrome and esophageal atresia: Coincidence or a digenic mode of inheritance? ( 29257230 )
2018
27
Correction to: Comprehensive Registry of Esophageal Cancer in Japan, 2011. ( 29948478 )
2018
28
Airborne and food sensitization patterns in children and adults with eosinophilic esophagitis. ( 29381255 )
2018
29
The role of endosonography prior to endoscopic treatment of esophageal cancer. ( 29963792 )
2018
30
Impaired FGF10 Signaling and Epithelial Development in Experimental Lung Hypoplasia With Esophageal Atresia. ( 29732364 )
2018
31
The experience of breastfeeding infants affected by congenital diaphragmatic hernia or esophageal atresia. ( 29970173 )
2018
32
Repair of congenital esophageal atresia with tracheoesophageal fistula repair in Ontario over the last 20years: Volume and outcomes. ( 29519572 )
2018
33
Epithelial origin of eosinophilic esophagitis. ( 29980278 )
2018
34
Esophagitis dissecans superficialis due to severe nonsteroidal anti-inflammatory drugs toxicity. ( 29907463 )
2018
35
Association of mast cells with clinical, endoscopic, and histologic findings in adults with eosinophilic esophagitis. ( 29935026 )
2018
36
Early diagnostic potential of<i>APC</i>hypermethylation in esophageal cancer. ( 29440928 )
2018
37
Successfully Conservative Management of Delayed Cervical Spondylodiscitis with Epidural Abscess Caused by Esophageal Diverticulitis: A Case Report and Review of Literature. ( 29883818 )
2018
38
Diagnosing conduit leak after esophagectomy for esophageal cancer by computed tomography leak protocol and standard esophagram: Is old school still the best? ( 29414520 )
2018
39
Impact of Esophageal Atresia on the Success of Fundoplication for Gastroesophageal Reflux. ( 29628411 )
2018
40
[Corrigendum] miRNA-1207-5p is associated with cancer progression by targeting stomatin-like protein 2 in esophageal carcinoma. ( 29393389 )
2018
41
A Long-Standing Primary Vaginal Paraganglioma-Coexisting with Esophageal Carcinoma. ( 29887722 )
2018
42
Intake of Dietary One-Carbon Metabolism-Related B Vitamins and the Risk of Esophageal Cancer: A Dose-Response Meta-Analysis. ( 29954131 )
2018
43
A novel method of endoscopic-assisted esophageal clearance in advanced achalasia. ( 29344565 )
2018
44
The Distended Fetal Hypopharynx: A Sensitive and Novel Sign for the Prenatal Diagnosis of Esophageal Atresia. ( 29622396 )
2018
45
Location of TEF at the carina as an indicator of long-gap C-type esophageal atresia. ( 29931283 )
2018
46
Cytology Preparations of Formalin Fixative Aid Detection of Giardia in Duodenal Biopsy Samples: A Helpful Tool for Diagnosing Esophageal Candidiasis as Well? ( 29762142 )
2018
47
Changing Concept of the Prevalence of Eosinophilic Esophagitis: Visible and Hidden Patients. ( 29969848 )
2018
48
Esophageal Large-Cell Neuroendocrine Carcinoma with Inconsistent Response to Treatment in the Primary and Metastatic Lesions. ( 29928189 )
2018
49
Esophageal carcinosarcoma comprised of minimally invasive squamous cell carcinoma and undifferentiated pleomorphic sarcoma: A collision cancer? ( 29934989 )
2018
50
ZNF750 Expression Is a Potential Prognostic Biomarker in Esophageal Squamous Cell Carcinoma. ( 29216641 )
2018

Variations for Esophagitis

Expression for Esophagitis

Search GEO for disease gene expression data for Esophagitis.

Pathways for Esophagitis

Pathways related to Esophagitis according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 CCL11 CXCL8 DSG1 EGFR IL13 IL1B
2
Show member pathways
13.83 CCL11 CCL26 CCR3 CXCL8 EGFR IL13
3
Show member pathways
13.58 CCL11 CCL26 CCR3 CXCL8 EGFR IL13
4
Show member pathways
13.5 CCL11 CCL26 CXCL8 EGFR IL13 IL1B
5
Show member pathways
13.34 CCL11 CXCL8 EGFR IL13 IL1B IL5
6
Show member pathways
13.34 CCL11 CCL26 CCR3 CXCL8 EGFR IL13
7
Show member pathways
13.24 CCL11 CCL26 CCR3 CXCL8 EGFR IL13
8
Show member pathways
12.86 CCL11 CXCL8 IL13 IL1B IL5 IL6
9 12.82 CXCL8 EGFR IL13 IL5 IL6 PTGS2
10
Show member pathways
12.78 CXCL8 IL13 IL1B IL6 TP53
11
Show member pathways
12.57 CXCL8 EGFR IL13 IL1B IL5 IL6
12
Show member pathways
12.56 CCR3 CXCL8 IL6 PTGS2 TP53
13
Show member pathways
12.45 EGFR IL13 IL1B IL5 TP53
14
Show member pathways
12.42 IL13 IL1B IL5 IL6
15
Show member pathways
12.33 CCL11 CCL26 CCR3 CXCL8
16
Show member pathways
12.32 IL1B IL6 PTGS2 TP53
17
Show member pathways
12.28 CXCL8 IL1B IL6 PTGS2 TP53
18
Show member pathways
12.24 CXCL8 EGFR IL1B IL6 PTGS2
19
Show member pathways
12.2 CCL11 CXCL8 IL13 IL1B IL5 IL6
20
Show member pathways
12.18 CCL11 CXCL8 IL1B IL6
21 12.18 EGFR IL6 PTGS2 TP53
22 12.16 CXCL8 IL13 IL1B IL6
23
Show member pathways
12.03 EGFR IL13 IL1B IL5 TP53
24
Show member pathways
12 CCL11 CCL26 CCR3 CXCL8
25 11.96 CXCL8 IL1B IL6 TP53
26 11.93 IL1B IL6 PTGS2
27 11.92 CXCL8 EGFR IL1B IL6 PTGS2 TP53
28 11.89 CXCL8 IL1B IL6
29 11.87 IL1B IL5 IL6
30 11.87 CXCL8 IL1B IL6
31
Show member pathways
11.87 CCL11 CCL26 CXCL8 EGFR IL13 IL1B
32 11.86 CXCL8 IL1B PTGS2
33 11.84 CXCL8 IL1B IL6
34 11.82 IL13 IL1B IL5 TSLP
35 11.81 CXCL8 IL1B IL6
36 11.79 CXCL8 IL13 IL5 IL6 TP53
37
Show member pathways
11.75 CXCL8 IL5 PTGS2
38 11.75 CXCL8 IL1B IL6
39 11.73 CXCL8 EGFR TP53
40
Show member pathways
11.69 CXCL8 IL1B IL6 PTGS2
41 11.67 CXCL8 EGFR IL6
42 11.65 CCL11 CCL26 IL5
43 11.59 CXCL8 IL1B IL6
44 11.58 CXCL8 IL6 PTGS2 TP53
45 11.56 EGFR IL6 TP53
46 11.56 CCL11 CXCL8 IL13 IL1B IL6 PTGS2
47 11.54 CXCL8 IL1B IL6
48 11.52 IL1B IL5 IL6
49 11.52 CCL11 CXCL8 IL6 TSLP
50 11.49 CCL11 IL13 IL5

GO Terms for Esophagitis

Cellular components related to Esophagitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 CCL11 CCL26 CXCL8 EGFR IL13 IL1B
2 extracellular space GO:0005615 9.32 CCL11 CCL26 CXCL8 EGFR IL13 IL1B

Biological processes related to Esophagitis according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.98 CXCL8 IL1B IL6 PTGS2 TP53
2 positive regulation of cell proliferation GO:0008284 9.95 EGFR IL1B IL5 IL6 PTGS2 TSLP
3 positive regulation of cell migration GO:0030335 9.9 CCL11 CCL26 EGFR IL1B
4 response to lipopolysaccharide GO:0032496 9.89 CXCL8 IL13 IL1B PTGS2
5 immune response GO:0006955 9.86 CCL11 CCL26 CXCL8 HRH2 IL13 IL1B
6 chemotaxis GO:0006935 9.85 CCL11 CCL26 CCR3 CXCL8
7 positive regulation of DNA binding transcription factor activity GO:0051091 9.84 IL1B IL5 IL6
8 response to estradiol GO:0032355 9.83 EGFR POSTN PTGS2
9 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.81 IL5 IL6 TP53
10 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.81 EGFR IL6 PTGS2
11 positive regulation of angiogenesis GO:0045766 9.81 CCL11 CCR3 CXCL8 IL1B
12 cellular response to interleukin-1 GO:0071347 9.8 CCL11 CCL26 CXCL8
13 positive regulation of inflammatory response GO:0050729 9.8 CCL26 EGFR TSLP
14 positive regulation of endothelial cell proliferation GO:0001938 9.79 CCL11 CCL26 CCR3
15 cellular response to drug GO:0035690 9.79 EGFR IL1B TP53
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.78 IL13 IL6 TSLP
17 cellular response to mechanical stimulus GO:0071260 9.76 EGFR IL13 IL1B PTGS2
18 regulation of signaling receptor activity GO:0010469 9.76 CCL11 CCL26 CXCL8 IL13 IL1B IL5
19 positive regulation of interleukin-6 production GO:0032755 9.75 IL1B IL6 TSLP
20 chemokine-mediated signaling pathway GO:0070098 9.73 CCL11 CCL26 CCR3 CXCL8
21 cellular response to tumor necrosis factor GO:0071356 9.72 CCL11 CCL26 CXCL8 POSTN TRPV1
22 monocyte chemotaxis GO:0002548 9.71 CCL11 CCL26 IL6
23 neutrophil chemotaxis GO:0030593 9.71 CCL11 CCL26 CXCL8 IL1B
24 positive regulation of nitric oxide biosynthetic process GO:0045429 9.7 IL1B PTGS2 TRPV1
25 positive regulation of vasoconstriction GO:0045907 9.67 EGFR HRH2 PTGS2
26 positive regulation of smooth muscle cell proliferation GO:0048661 9.67 EGFR IL13 IL6 PTGS2
27 microglial cell activation GO:0001774 9.66 IL13 TRPV1
28 cellular response to ATP GO:0071318 9.65 PTGS2 TRPV1
29 positive regulation of immunoglobulin secretion GO:0051024 9.65 IL5 IL6
30 positive regulation of fever generation GO:0031622 9.57 IL1B PTGS2
31 fever generation GO:0001660 9.56 IL1B TRPV1
32 cytokine-mediated signaling pathway GO:0019221 9.56 CCL11 CXCL8 IL13 IL1B IL5 IL6
33 inflammatory response GO:0006954 9.32 CCL11 CCL26 CCR3 CXCL8 IL13 IL1B
34 positive regulation of transcription, DNA-templated GO:0045893 10.06 EGFR IL1B IL5 IL6 TP53
35 negative regulation of apoptotic process GO:0043066 10.04 EGFR IL6 PTGS2 TP53 TSLP

Molecular functions related to Esophagitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.33 CCL11 CCL26 CXCL8
2 cytokine activity GO:0005125 9.23 CCL11 CCL26 CXCL8 IL13 IL1B IL5
3 CCR3 chemokine receptor binding GO:0031728 8.96 CCL11 CCL26

Sources for Esophagitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....